Private clinics accuse health minister of ‘complicity or absence' in face of NACCOL ‘overreach'
FPMPAM president Dr Shanmuganathan Ganeson criticised Datuk Seri Dzulkefly Ahmad for keeping silent when the deputy minister of domestic trade and cost of living cited NACCOL's 'mandate' in Parliament to justify new rules for private clinics.
'These were policy suggestions, not legally binding directives, but the way they were presented has caused widespread confusion,' Dr Shanmuganathan said in a statement.
He said the minister's failure to speak up during NACCOL meetings showed either 'complicity or absence' in protecting the medical profession.
'The full responsibility — and the failure — lies with the minister of health himself,' he said.
FPMPAM also criticised the government for pushing mandatory drug price displays and prescriptions without proper legal authority or consultation.
Dr Shanmuganathan said clinical decisions such as issuing prescriptions or itemised billing fall under the Ministry of Health and Malaysian Medical Council (MMC), not NACCOL.
He argued that forced itemised billing could increase healthcare costs for patients.
'We are not NACCOL's subjects. We are the custodians of patient care,' he said.
The association then demanded that the minister publicly state his position and take steps to restore trust among private medical professionals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Analysis-Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters
By Lewis Krauskopf NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some investors are betting that the beaten-down shares are now becoming too much of a bargain to pass up. The S&P 500 healthcare sector -- which includes pharmaceutical companies, biotechs, health insurers and medical equipment makers -- has slumped 5% in 2025, lagging the over 7% gain for the overall index. Pressure to bring down U.S. prescription drug prices to overseas rates, tariffs targeted at pharmaceuticals and cuts to areas such as health research funding and Medicaid are among the Trump administration actions clouding the outlook for the shares this year, investors said. Regulatory obstacles are compounding issues, including expiring drug patents and setbacks for bellwethers including UnitedHealth Group. "You have got this constant overarching political and regulatory overhang that doesn't really seem to subside with any administration," said Jared Holz, healthcare sector strategist at Mizuho Securities. "When you have so much nebulousness around the sector, it turns people off rather than invites them to the party." In another sign of the group losing favor, healthcare exchange-traded-funds have seen 12 consecutive months of net outflows as of July for a total outflow of $11.5 billion in that time, more than for any other sector, according to State Street Investment Management. The performance picture is even dimmer over a longer period. While shares of massive technology companies pushed the benchmark S&P 500 up over 50% the past three years, the healthcare sector is little changed in that time. That gap has put the 60-stock sector at nearly its biggest discount to the broader market in 30 years, which some investors hope is an inflection point for the battered group. "The valuation is extremely cheap and the relative performance is at an extreme," said Walter Todd, chief investment officer at Greenwood Capital, whose healthcare holdings include diversified giant Johnson & Johnson and medical device maker Stryker. "So at this point, it seems like a pretty decent setup to get some outperformance." The price-to-earnings ratio for the healthcare sector, based on earnings estimates for the next year, has fallen to 16.2 times from nearly 20 a year ago, according to LSEG Datastream. Meanwhile, the S&P 500's rally to records has driven the index's P/E ratio to over 22 times -- giving the broader market a significant premium over the healthcare sector. 'BAD NEWS IS PRICED IN' Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, against its long-term average of 14.5, while fellow drugmaker Bristol Myers Squibb trades at 7.4 against its average of 15.8, according to LSEG. Year-to-date, shares of both Merck and Bristol Myers are down roughly 20%. The group is drawing bets from some value investors such as Patrick Kaser, portfolio manager at Brandywine Global, whose portfolio is overweight the sector including owning shares of CVS Health and European drugmakers GSK and Sanofi. "Our perspective is a lot of this bad news is priced in and then some," Kaser said. "To bet against the sector from here, you're essentially continuing to bet on the valuation gap, which is already large, continuing to widen." The group's decline means the total market value of the S&P 500 healthcare sector is about $4.8 trillion, not much higher than the $4.3 trillion value of Nvidia, the semiconductor company that has symbolized the artificial intelligence boom. Indeed, some investors said a shift in capital away from Nvidia and other massive tech companies could spark healthcare shares. Such a move appeared to occur in the first quarter, investors said, when the healthcare sector rose 6% while declines in tech and megacap stocks dragged indexes lower. Fears of an economic downturn also could help healthcare shares, at least on a relative basis. The group is often viewed as a defensive area in rockier economic times. Economic fears flared following last Friday's weaker-than-expected employment report, while some strategists say the market could be due for a pullback after surging over 20% since its April lows. "During the first quarter, healthcare did great even as tech rolled over, as the fears of an economic slowdown got to more economically sensitive stocks," said Chris Grisanti, chief market strategist at MAI Capital Management, adding he expects healthcare "will perform better in a more difficult market." More clarity on regulatory issues, including tariffs, also could support healthcare, investors said. But some value investors are hesitant to dive into the group. Michael Mullaney, director of global markets research at Boston Partners, said he is wary some healthcare shares could be "value traps," preferring to overweight areas including industrials or financials. "There's been just so much of an overhang in the sector," Mullaney said. "There are better places to go with cleaner stories." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Audien Hearing Enters Walgreens Stores Nationwide, Signaling Major Retail Expansion
Walgreens will carry top-selling Audien hearing aids in thousands of locations SCOTTSDALE, Ariz., Aug. 7, 2025 /PRNewswire/ -- Audien Hearing, the No. 1-selling over-the-counter (OTC) hearing aid brand, today announced that its flagship Atom One and Atom Pro 2 hearing aids will be available in Walgreens stores, as well as on and in the Walgreens app, this month. The rollout marks Audien's entry into retail pharmacy, advancing its mission to make hearing support more affordable and accessible for everyone. Audien products will be available in nearly 2,000 Walgreens stores in August, expanding to more than 4,400 stores by mid-November. The rollout reflects Audien's broader shift into omnichannel distribution to tackle the global challenge of hearing loss - which affects over 1 billion people - by making highly functional, discreet hearing solutions widely available starting at only $98. "Launching in Walgreens is more than expanding our distribution, it's about making hearing care easier to access for everyone," said Ishan Patel, CEO of Audien Hearing. "With Walgreens' deep commitment to care, trust, and accessibility, we're proud to collaborate with them to bring effective hearing solutions to customers without prescriptions, appointments, or high costs." "At Walgreens, we're committed to meeting people where they are in their health journey and that includes making hearing support easier to access," said Tracey Koller, chief merchandising officer, Walgreens. "Collaborating with Audien allows us to bring more affordable, effective hearing solutions to our customers and helps them live healthier and happier lives. Audien's launch into Walgreens will help reach more individuals experiencing hearing changes who are looking for convenient, effective solutions. With over 1 million people already served through its OTC offering, this expansion helps fulfill Audien's vision of Hearing for Everyone® by increasing its physical retail footprint to match its impact. To learn more or find a participating store, visit About Audien HearingAudien Hearing is the No. 1-selling OTC hearing aid brand in the world, serving over 1 million online customers and carried by thousands of major retail stores across the US. Founded by three grandsons inspired by their grandparents' hearing struggles, Audien is on a mission to tear down the barriers between people and better health - giving everyone the power to hear clearly, connect deeply, and live freely. With a growing product line, a values-driven team, and a commitment to impact, the company is redefining what hearing health can and should look like. Learn more at View original content to download multimedia: SOURCE Audien Hearing Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Wegovy, Mounjaro sales in India double on month in July
By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday. Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world's most populous nation. Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data showed. Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees. "Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement. In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes. Mounjaro's sales have soared 15 times since March, when the drug was launched in India. ($1 = 87.6790 Indian rupees) Sign in to access your portfolio
